新闻动态 News
查看更多 >>
-
2022-01-09近日,经北京市人力资源和社会保障局、全国博士后管委会批准,北京望石智慧科技有限公司(以下简称“望石智慧”)获批设立博士后科研工作站。这是对望石智慧在AI药物研发领域的基础理论研究、创新技术成果和高层次人才培养等方面的重大认可。未来,望石智慧将进一步探索AI制药技术新边界,大力推进产、学、研的新融合。 博士后科研工作站作为产、学、研结合的纽带,是驱动企业研发创新、探索新技术边界和培养高层次人才的重要载体。 AI制药基础理论的突破和技术的落地,是望石智慧博士后工作站获批的重要原因。望石智慧一直致力于AI驱动的新药研发,构建了体系化的AI新药早期研发系统,以及高效实用的工具平台StoneMIND®;同时,在AI制药的理论基础层面上也有创新,例如在全球范围内首次实现基于多分辨率电子密度的3D分子生成技术,尝试将AI药物发现的范式从原有的“先有库后筛选”变为更高效的“根据目标精准生成”。 挂牌后,望石智慧博士后科研工作站将逐步完善与国内外顶尖高校...
-
2021-10-20日前,全球领先的人工智能新药研发平台北京望石智慧科技有限公司(以下简称“望石智慧”),与全球化专业制药企业浙江海正药业股份有限公司(以下简称“海正药业”)共同宣布,双方达成合作开发协议。 根据已签署的协议,双方将充分利用各自技术、团队与资源优势,携手开展针对某First-in-Class靶点的抗肿瘤小分子药物的研发。 望石智慧的AI技术平台将靶点口袋研究、分子生成、超高通量筛选、化合物与靶标蛋白的精准结合能计算以及成药性预测等多个技术模块高度整合,能在合作中极大加速项目的早期研发。其近期发布的电子云密度为分子表征的底层技术和基于口袋的3D分子生成技术,为工业界首次实现,在First-in-Class药物的HIT发现中有独特优势。 海正药业是集原料药和制剂研发,生产和销售一体化的国际化综合型制药企业,荣获首批“创新型企业”、“国家高新技术企业”、“国家知识产权示范企业”等多项荣誉。公司从2006年开始布局创新药,第一个1.1类创新药海博麦布于今年6月获批上市,成为近年来...
-
2021-10-20摩根大通(J.P. Morgan)于10月12日-13日在上海成功举办了首届全球医疗健康产业年会上海论坛。望石智慧CEO周杰龙应邀参与“人工智能在医疗领域的前沿应用”的圆桌讨论。 摩根大通集团是一家全球领先的金融服务公司。摩根大通全球医疗健康产业年会(The annual J.P. Morgan Health Care Conference)是业内规模最大、最负盛名的医疗健康投资研讨会,汇集了顶尖医疗健康专家、商业领袖和投资团体。 圆桌讨论嘉宾:望石智慧 周杰龙(右一) 英矽智能 Alex(右二) 医渡科技 杨晶(右三) 数坤科技 马春娥(左二) 讨论中,望石智慧CEO周杰龙表示: 望石智慧定位为技术驱动的平台型公司,致力于药物早期研发应用场景的平台系统开发,带着对医药研发的敬畏之心和不断的认知迭代,持续进行新技术的摸索。大平台大系统是我们系统研发的一贯理念,通过软件、系统和数据的结合,充分发挥AI在相关应用场景的优势。 国内创新药研发的需求日渐旺盛, AI基于数据的快速...
-
2021-08-12首次发布:基于电子云密度的3D分子生成模型和结合模式分析模型 ACS将在2021年8月22-26日举行秋季年会线上会议。望石智慧共有四篇Poster被会务组接收,其中两篇被会务组邀请进行演讲。 望石智慧创造性地利用多分辨率电子密度表示分子和非共价相互作用,使PDB中大量的电子云密度数据用于模型训练成为可能,该应用为工业界首次。利用该类型数据、机器学习模型和传统的QTAIM理论, 望石智慧开发了独特的3D生成模型和基于电子云密度的结合模式的分析。该部分技术的最新进展会在会议的Posters中披露,Posters日程如下: Poster 1 Achieving quantum mechanics level quantification of noncovalent interactions in protein-ligand complex with limited time cost by using machine learning model (Paper ID: 3589413) 论坛: Sci-Mix 日期时间:(北京时间)8/24/2021 8:00 AM - 10:00 AM 论坛: Emerging Tech 参会形式:Oral - Virtual 日期时间:(北京时间)8/26/2021 5:45 AM - 6:05 AM Poster 2 Pocke...
-
2021-08-03近日,中国领先的生物制药公司翰森制药集团有限公司(HKEX:3692)(“翰森制药”)和AI赋能小分子创新药研发企业北京望石智慧科技有限公司(“望石智慧”)宣布,双方就创新药物研发达成合作伙伴关系。根据合作协议,双方将充分利用各自技术、团队与资源优势,针对多个疾病领域未被满足的迫切临床需求,共同进行创新药物开发。望石智慧拥有AI赋能的药物分子设计平台与产业经验丰富的复合型药物研发团队,将靶点口袋研究、分子生成、超高通量筛选、化合物与靶标蛋白的精准结合能计算以及成药性预测等多个技术模块高度整合,在合作中极大加速项目的早期研发进程。翰森制药将基于行业领先的研发、生产和商业化能力加速产品的发现和开发进程。 关于翰森制药 翰森制药的主要经营主体豪森药业成立于1995年,是中国领先的创新驱动型制药公司,秉持“做优民族医药,做强中国创造”的企业使命,致力于通过持续创新改善人类健康,重点关注抗肿瘤、中枢神经系统、抗感染和糖尿病等重大疾病治疗领域。目前已通过自主研发成功...
-
2021-07-05专注于小分子药物研发的AI技术平台型公司——望石智慧宣布上海研发中心正式成立。 望石智慧上海研发中心位于上海张江医药研发核心区域,旨在汇聚全球顶尖的创新药研发人才,为合作伙伴提供从技术到完整复合团队的支持。 “此次建立上海新药研发中心,是望石智慧的又一项重要战略举措,它将与北京和波士顿的团队共同合作,开展研究,同时也将加强团队与长三角地区合作伙伴的互动。我们将整合国内外顶尖专家和学者的资源和能力,优势互补,协力创新。” 公司创始人&CEO 周杰龙 望石智慧一直致力于AI赋能医药研发体系化,目前为新药研发企业提供医药知识图谱、超高通量虚拟筛选、高通量精准对接、分子生成与设计、活性预测、ADMET预测、合成可及性预测和定制化模型等一体化解决方案,以提升新药研发中药物发现、设计、合成等关键环节的效率和成功率。 过去两年中,望石智慧与合作伙伴们在多个高难度的新药研发项目中,取得了突破性的试验结果。随着合作伙伴数量的持续增加,各种新机制或类型的项目也相应增多。上海新药...
学术进展 Academic Progress
查看更多 >>
-
2023-07-07Yucui Xin, Yingsheng Zhang DOI: https://doi.org/10.3389/fonc.2023.1168143 Abstract: Tumor cells can result from gene mutations and over-expression. Synthetic lethality (SL) offers a desirable setting where cancer cells bearing one mutated gene of an SL gene pair can be specifically targeted by disrupting the function of the other genes, while leaving wide-type normal cells unharmed. Paralogs, a set of homologous genes that have diverged from each other as a consequence of gene duplication, make the concept of SL feasible as the loss of one gene does not affect the cell’s survival. Furthermore, homozygous loss of paralogs in tumor cells is more frequent than singletons, making them ideal SL targets. Although high-throughput CRISPR-Cas9 screenings have uncovered numerous paralog-based SL pairs, the unclear mechanisms of targeting these gene pairs and the...
-
2023-05-30Weisheng Zheng, Mengchen Pu, Xiaorong Li, Zhaolan Du, Sutong Jin, Xingshuai Li, Jielong Zhou, Yingsheng Zhang DOI: https://doi.org/10.1038/s41598-023-35842-w Abstract: Metastatic propagation is the leading cause of death for most cancers. Prediction and elucidation of metastatic process is crucial for the treatment of cancer. Even though somatic mutations have been linked to tumorigenesis and metastasis, it is less explored whether metastatic events can be identified through genomic mutational signatures, which are concise descriptions of the mutational processes. Here, we developed MetaWise, a Deep Neural Network (DNN) model, by applying mutational signatures as input features calculated from Whole-Exome Sequencing (WES) data of TCGA and other metastatic cohorts. This model can accurately classify metastatic tumors from primary tumors and outpe...
-
2023-05-22Feng Zhou, Shiqiu Yin, Yi Xiao, Zaiyun Lin, Weiqiang Fu, and Yingsheng J. Zhang DOI: https://doi.org/10.1021/acsomega.3c02294 Abstract: Drug design based on kinetic properties is growing in application. Here, we applied retrosynthesis-based pre-trained molecular representation (RPM) in machine learning (ML) to train 501 inhibitors of 55 proteins and successfully predicted the dissociation rate constant (koff) values of 38 inhibitors from an independent dataset for the N-terminal domain of heat shock protein 90α (N-HSP90). Our RPM molecular representation outperforms other pre-trained molecular representations such as GEM, MPG, and general molecular descriptors from RDKit. Furthermore, we optimized the accelerated molecular dynamics to calculate the relative retention time (RT) for the 128 inhibitors of N-HSP90 and obtained the protei...
-
2023-03-23Zaiyun Lin, Shiqiu Yin, Lei Shi, Wenbiao Zhou, and Yingsheng John Zhang DOI: https://doi.org/10.1021/acs.jcim.2c01302 Abstract: Retrosynthesis prediction, the task of identifying reactant molecules that can be usedto synthesize product molecules, is a fundamental challenge in organic chemistry and related fields.To address this challenge, we propose a novel graph-to-graph transformation model, G2GT. Themodel is built on the standard transformer structure and utilizes graph encoders and decoders.Additionally, we demonstrate the effectiveness of self-training, a data augmentation technique thatutilizes unlabeled molecular data, in improving the performance of the model. To further enhancediversity, we propose a weak ensemble method, inspired by reaction-type labels and ensemblelearning. This method incorporates beam search, nucleus sampling, and top-k sampling to im...
-
2023-02-28Li, Y., Yuan, T., Huang, B. et al. Nat Commun 14, 1030 (2023). https://doi.org/10.1038/s41467-023-36766-9 Abstract The sodium channel NaV1.6 is widely expressed in neurons of the central and peripheral nervous systems, which plays a critical role in regulating neuronal excitability. Dysfunction of NaV1.6 has been linked to epileptic encephalopathy, intellectual disability and movement disorders. Here we present cryo-EM structures of human NaV1.6/β1/β2 alone and complexed with a guanidinium neurotoxin 4,9-anhydro-tetrodotoxin (4,9-ah-TTX), revealing molecular mechanism of NaV1.6 inhibition by the blocker. The apo-form structure reveals two potential Na+ binding sites within the selectivity filter, suggesting a possible mechanism for Na+ selectivity and conductance. In the 4,9-ah-TTX bound structure, 4,9-ah-TTX bin...
-
2022-10-09Cell. October 04, 2022 DOI:https://doi.org/10.1016/j.cell.2022.09.037 Liming Yan, Yucen Huang, Ji Ge, Zhenyu Liu, Pengchi Lu, Bo Huang, Shan Gao, Junbo Wang, Liping Tan, Sihan Ye, Fengxi Yu, Weiqi Lan, Shiya Xu, Feng Zhou, Lei Shi, Luke W. Guddat, Yan Gao, Zihe Rao, Zhiyong Lou Summary Decoration of cap on viral RNA plays essential roles in SARS-CoV-2 proliferation. Here we report a mechanism for SARS-CoV-2 RNA capping and document structural details at atomic resolution. The NiRAN domain in polymerase catalyzes the covalent link of RNA 5’ end to the first residue of nsp9 (termed as RNAylation), thus being an intermediate to form cap core (GpppA) with GTP catalyzed again by NiRAN. We also reveal that triphosphorylated nucleotide analogue inhibitors can be bonded to nsp9 and fi...